Prelude Capital Management, LLC Neu Base Therapeutics, Inc. Transaction History

Prelude Capital Management, LLC

  • $1.57 Billion
  • Q3 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2020

Feb 16, 2021
BUY
$6.92 - $9.25 $2.15 Million - $2.88 Million
311,000 New
311,000 $2.17 Million

About NeuBase Therapeutics, Inc.

NBSE Quotes by TradingView
  • Ticker NBSE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,258,700
  • Description
  • NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as ...
More about NBSE
Track This Portfolio

Track Prelude Capital Management, LLC Portfolio

Follow Prelude Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prelude Capital Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email